

# Samuel S Engel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4521105/publications.pdf>

Version: 2024-02-01

39  
papers

3,852  
citations

361413  
20  
h-index

289244  
40  
g-index

40  
all docs

40  
docs citations

40  
times ranked

4656  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 232-242.	27.0	2,188
2	Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Current Medical Research and Opinion, 2016, 32, 1243-1252.	1.9	315
3	Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocrine Disorders, 2010, 10, 7.	2.2	234
4	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care, 2016, 39, 2304-2310.	8.6	142
5	Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The <scp>VERTIS FACTORIAL</scp> randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 1111-1120.	4.4	121
6	Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies. Diabetes Therapy, 2013, 4, 119-145.	2.5	109
7	Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovascular Diabetology, 2013, 12, 3.	6.8	84
8	A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2017, 16, 112.	6.8	78
9	The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes* <sup>&lt;sup&gt;â€&lt;/sup&gt;</sup> . Journal of Diabetes, 2012, 4, 227-237.	1.8	56
10	Assessing occurrence of hypoglycemia and its severity from electronic health records of patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2016, 121, 192-203.	2.8	52
11	Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care, 2017, 40, 494-501.	8.6	50
12	Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. Diabetes, Obesity and Metabolism, 2017, 19, 1425-1435.	4.4	39
13	A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine. Diabetes Therapy, 2015, 6, 127-142.	2.5	37
14	Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes: A Pooled Analysis of 25 Clinical Studies. Drugs and Aging, 2014, 31, 203-214.	2.7	33
15	A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSITâ€R study. Diabetes, Obesity and Metabolism, 2018, 20, 2876-2884.	4.4	33
16	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. Diabetes, Obesity and Metabolism, 2018, 20, 2379-2388.	4.4	29
17	Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy. Journal of Diabetes and Its Complications, 2014, 28, 831-835.	2.3	24
18	Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Diabetes, Obesity and Metabolism, 2017, 19, 1587-1593.	4.4	24

#	ARTICLE	IF	CITATIONS
19	Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2016, 7, 727-736.	2.4	23
20	Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (<sc>DPP</sc>-4) inhibitor omarigliptin or the once-daily <sc>DPP</sc>-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 394-400.	4.4	23
21	A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in <sc>J</sc>apanese patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1602-1609.	4.4	19
22	Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-1 Study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 781-790.	4.4	19
23	Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin. <i>Pediatric Diabetes</i> , 2022, 23, 183-193.	2.9	14
24	A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes. <i>Pediatric Diabetes</i> , 2022, 23, 173-182.	2.9	13
25	Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2017, 8, 321-329.	2.4	12
26	Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials. <i>Diabetes Therapy</i> , 2015, 6, 29-40.	2.5	10
27	A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone. <i>Current Medical Research and Opinion</i> , 2017, 33, 693-699.	1.9	10
28	Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 821-830.	4.4	9
29	Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database. <i>Diabetes Therapy</i> , 2018, 9, 309-315.	2.5	7
30	Progression of glucose-lowering diabetes therapy in TECOS. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00053.	2.4	7
31	Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-1M study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1128-1135.	4.4	7
32	Characterization of Sitagliptin Use in Patients with Type 2 Diabetes and Chronic Kidney Disease by Cross-Sectional Analysis of a Medical Insurance Claims Database. <i>Diabetes Therapy</i> , 2015, 6, 627-634.	2.5	5
33	A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control. <i>Diabetes Therapy</i> , 2017, 8, 793-810.	2.5	5
34	Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2099-2108.	4.4	5
35	A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1242-1251.	4.4	4
36	Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials. <i>Diabetes Therapy</i> , 2018, 9, 1581-1589.	2.5	3

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Peopleâ€™s 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency. Diabetes Therapy, 2020, 11, 2419-2428.	2.5	3
38	Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin. Diabetes, Obesity and Metabolism, 2019, 21, 408-411.	4.4	2
39	A randomized, placeboâ€™controlled trial to assess the efficacy and safety of sitagliptin in J apanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin. Diabetes, Obesity and Metabolism, 2021, 23, 1342-1350.	4.4	2